Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gossamer Bio (GOSS) EBIT (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of EBIT data on record, last reported at -$49.1 million in Q3 2025.

  • For Q3 2025, EBIT fell 44.8% year-over-year to -$49.1 million; the TTM value through Sep 2025 reached -$160.8 million, down 120.85%, while the annual FY2024 figure was -$59.9 million, 67.39% up from the prior year.
  • EBIT reached -$49.1 million in Q3 2025 per GOSS's latest filing, down from -$38.8 million in the prior quarter.
  • Across five years, EBIT topped out at $52.1 million in Q2 2024 and bottomed at -$56.0 million in Q3 2022.
  • Average EBIT over 4 years is -$39.1 million, with a median of -$46.3 million recorded in 2023.
  • Peak YoY movement for EBIT: skyrocketed 212.5% in 2024, then crashed 174.42% in 2025.
  • A 4-year view of EBIT shows it stood at -$54.4 million in 2022, then rose by 9.81% to -$49.0 million in 2023, then grew by 26.31% to -$36.1 million in 2024, then tumbled by 35.94% to -$49.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$49.1 million in Q3 2025, -$38.8 million in Q2 2025, and -$36.8 million in Q1 2025.